The company said it intends to reaffirm its diluted earnings per common share (EPS) guidance of approximately $14.87 for the fiscal year ending December 31, 2024 (FY 2024).

1. 01

   The company said it intends to reaffirm its diluted earnings per common share (EPS) guidance of approximately $14.87 for the fiscal year ending December 31, 2024 (FY 2024).

2. 02

   Humana said it intends to reaffirm its adjusted earnings per common share (Adjusted EPS) guidance of approximately $16.00 for FY 2024, and that this guidance is consistent with the guidance in its press release dated January 25, 2024.

3. 03

   The company said its FY 2024 GAAP EPS of approximately $14.87, adjusted for 0.49 of amortization of identifiable intangibles, 0.97 from the exit of the employer group commercial medical products business, and a cumulative net tax impact of non-GAAP adjustments of (0.33), results in Adjusted EPS of approximately $16.00.

4. 04

   The company said its management team will meet with investors and analysts at an industry conference and other meetings from March 5, 2024 to March 31. It also said it uses Adjusted EPS to compare core operating performance over time, for planning and decision-making, and to determine incentive compensation, and that Adjusted EPS does not replace GAAP EPS.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.